Ladenburg upgraded Acrivon Therapeutics to Buy from Neutral with a $16 price target. The company reported an “impressive” 63% overall response rate in endometrial cancer patients who had either progressed on or were ineligible for prior PD-1 therapy, the analyst tells investors in a research note. The firm cites the company’s achievement in demonstrating “such a high, albeit early” response rate in PD-1-failed endometrial cancer patients for the upgrade.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACRV:
- Acrivon Therapeutics upgraded to Buy from Neutral at Ladenburg
- Acrivon reports data from ongoing ACR-368 registrational intent Phase 2 study
- Acrivon Therapeutics Reports Positive Endometrial Cancer Data from Ongoing ACR-368 Registrational Intent Phase 2 Study at ESMO, Advancement of ACR-2316 into Clinic Ahead of Timelines, and Progress on its AP3 Interactome for Proprietary Data Analysis
- Acrivon Therapeutics to host investor event on Phase 2 data of ACR-368
- Acrivon Therapeutics price target lowered to $18 from $21 at Oppenheimer